Basic Stats
| LEI | 549300J8WJIVTOJ8IH97 |
| CIK | 1294133 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inogen, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 11111 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOG |
|
| August 8, 2025 |
Change of Control Agreement by and between the Company and Mary Wright, dated October 18, 2022. Exhibit 10.7 October 18, 2022 Dear Mary, As a result of your recent promotion to VP, Financial Reporting and Technical Accounting, effective as of July 18, 2022, the Company agrees to provide severance benefits that may be payable upon certain qualifying employment termination events, subject to the terms and conditions set forth below. In consideration of the promises and mutual covenants contain |
|
| August 8, 2025 |
Exhibit 10.5 INOGEN INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this “Agreement”), is made and effective as of February 14, 2022 (the "Effective Date"), by and between Inogen, Inc., a Delaware corporation (the "Company"), and Jennifer M. Yi Boyer (the "Executive"). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Exec |
|
| August 8, 2025 |
Appointment Letter by and between the Company and Mary Wright, dated July 25, 2025. Exhibit 10.8 July 25, 2025 Mary Wright Dear Mary, Congratulations on your promotion to VP, Chief Accounting Officer, effective July 28, 2025. The annual salary for this position will be $312,000, and you will continue to be paid on a bi-weekly basis. With this promotion your annual bonus target will remain 35%. Your new position will continue to report to Mike Bourque and your job description and |
|
| August 8, 2025 |
Appointment Letter by and between the Company and Jennifer Yi Boyer, dated July 25, 2025. Exhibit 10.6 Jennifer Yi Boyer Dear Jen, Congratulations on your appointment to EVP, Enterprise Enablement & Chief Human Resources Officer. The annual salary for this position will remain $430,000 and you will continue to be paid on a bi-weekly basis. With this appointment your annual bonus target will remain 50%. Your position will continue to report to Kevin Smith and your job description and du |
|
| August 7, 2025 |
Exhibit 99.1 Inogen Announces Second Quarter 2025 Financial Results Delivered strong top-line results; raising full year 2025 revenue expectations GOLETA, Calif., August 7, 2025 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025. Recent Highlights |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 001-36309 33-0989359 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 859 Ward Drive, Goleta, CA 93111 (Address of principal executive offices) (Zip Code) M |
|
| May 29, 2025 |
Inogen, Inc. Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Inogen, Inc. Conflict Minerals Report For The Reporting Period from January 1, 2024 to December 31, 2024 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Inogen’s objectives for its conflict minerals polic |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025 As filed with the Securities and Exchange Commission on May 20, 2025 Registration Statement No. |
|
| May 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inogen, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per |
|
| May 19, 2025 |
Exhibit 10.3 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (TIME-BASED) Unless otherwise defined herein, the terms defined in the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (Time-Based) (this “Award Agreement”), which includes the Notice of Restr |
|
| May 19, 2025 |
Amended and Restated 2023 Equity Incentive Plan Exhibit 10.1 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive S |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 19, 2025 |
Form of Stock Option Agreement under the Amended and Restated 2023 Equity Incentive Plan Exhibit 10.2 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Agreement (the “Agreement”), including the Notice of Stock Option Grant (the “Notice of Grant”) and Terms and Cond |
|
| May 19, 2025 |
Exhibit 10.4 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (PERFORMANCE-BASED) Unless otherwise defined herein, the terms defined in the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (Performance-Based) (this “Award Agreement”), which includes the N |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, I |
|
| May 7, 2025 |
Inogen Announces First Quarter 2025 Financial Results Exhibit 99.1 Inogen Announces First Quarter 2025 Financial Results GOLETA, Calif., May 7, 2025 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. “Inogen’s strong first quarter financial results underscore our success in driving improved commerc |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) Defin |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin |
|
| February 28, 2025 |
Outside Director Compensation Policy Exhibit 10.12 INOGEN, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved October 11, 2013, as amended January 6, 2014, July 22, 2015, September 3, 2015, October 25, 2017, September 29, 2020, July 28, 2021 and July 27, 2023. Inogen, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Bo |
|
| February 28, 2025 |
Inogen, Inc. Insider Trading Policy Exhibit 19.1 INOGEN, INC. INSIDER TRADING POLICY (As amended and restated on February 27, 2023) A. POLICY OVERVIEW Inogen, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize its own leg |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration Statement No. |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name |
|
| February 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inogen, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Common Stock, par value $0.0 |
|
| February 28, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Inogen Inc. Subsidiaries of the Registrant At February 21, 2025, the Registrant owned the following subsidiaries: Name State or Jurisdiction of Incorporation Inogen Europe, B.V. Netherlands Physio Assist SAS France Physio Assist GmbH Germany Inogen Inc. directly owns 100% of the outstanding voting securities of each of the above-named subsidiaries. |
|
| February 25, 2025 |
Inogen Announces Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Inogen Announces Fourth Quarter and Full Year 2024 Financial Results • Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% • Company Provides 2025 Growth Outlook • Recently Announced Strategic Collaboration with Yuwell to Expand Product Portfolio, Global Reach GOLETA, Calif., February 25, 2025 - Inogen, Inc. (Nasdaq: INGN), a medical tec |
|
| February 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 24, 2025 |
Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without th |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 3, 2025 |
Exhibit 99.1 Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West GOLETA, Calif., February 3, 2025 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen’s Board of Directors, effective January 31, 2 |
|
| January 27, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2025, is entered into by and between Inogen, Inc., a Delaware corporation (the “Company”), and Yuwell (Hong Kong) Holdings Limited, a company established under the laws of Hong Kong (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise |
|
| January 27, 2025 |
Exhibit 10.1 Strategic Collaboration Agreement This Strategic Collaboration Agreement (this “Agreement”), dated as of January 25, 2025 (“Effective Date”), is entered into by and between: (1) Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., a company organized and existing under the laws of the People’s Republic of China (“Yuwell”), and (2) Inogen Inc., a corporation organized and existing under |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2025 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 27, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 25, 2025, by and between Inogen, Inc., a Delaware corporation (the “Company”), and Yuwell (Hong Kong) Holdings Limited, a company established under the laws of Hong Kong (together with its permitted assigns, the “Investor”). WHEREAS, the Company and the Investor are executing and |
|
| January 27, 2025 |
Exhibit 99.1 Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration with Yuwell GOLETA, Calif., January 26, 2025 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supp |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 13, 2025 |
Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue Exhibit 99.1 Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue GOLETA, Calif., January 13, 2025 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024. The Company estimates prelimi |
|
| December 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 30, 2024 |
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device Exhibit 99.1 Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device GOLETA, Calif., – December 30, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, exp |
|
| November 14, 2024 |
INGN / Inogen, Inc. / Divisadero Street Capital Management, LP Passive Investment SC 13G/A 1 d1152810113g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inogen, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45780L104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGE |
|
| November 7, 2024 |
Inogen Announces Third Quarter 2024 Financial Results Exhibit 99.1 Inogen Announces Third Quarter 2024 Financial Results GOLETA, Calif., – November 7, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2024. “We continued to make significant progress on our strategic priorities in the third quar |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, IN |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 6, 2024 |
Inogen Announces Second Quarter 2024 Financial Results Exhibit 99.1 Inogen Announces Second Quarter 2024 Financial Results GOLETA, Calif., – August 6, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2024. “I am proud of the performance of our team in the first half of 2024. We have made meaningful |
|
| July 31, 2024 |
Transition Agreement and Release by and between the Company and Jason M. Somer, dated July 26, 2024 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Jason M. |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 3, 2024 |
Exhibit 99.1 Inogen Strengthens Leadership Team with Appointment of New General Counsel and Executive Vice President, Business Development GOLETA, Calif., July 3, 2024 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, |
|
| July 3, 2024 |
Exhibit 10.1 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this “Agreement”) is made and effective as of July 22, 2024 (the "Effective Date"), by and between Inogen, Inc., a Delaware corporation (the "Company"), and Kevin P. Smith (the "Executive"). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Executive's em |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 02, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inogen, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per sh |
|
| June 12, 2024 |
As filed with the Securities and Exchange Commission on June 12, 2024 As filed with the Securities and Exchange Commission on June 12, 2024 Registration Statement No. |
|
| June 7, 2024 |
Form of Stock Option Agreement under the Amended and Restated 2023 Equity Incentive Plan Exhibit 10.2 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Agreement (the “Agreement”), including the Notice of Stock Option Grant (the “Notice of Grant”) and Terms and Cond |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 7, 2024 |
Exhibit 10.4 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (PERFORMANCE-BASED) Unless otherwise defined herein, the terms defined in the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (Performance-Based) (this “Award Agreement”), which includes the N |
|
| June 7, 2024 |
Amended and Restated 2023 Equity Incentive Plan Exhibit 10.1 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive S |
|
| June 7, 2024 |
Exhibit 10.3 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (TIME-BASED) Unless otherwise defined herein, the terms defined in the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (Time-Based) (this “Award Agreement”), which includes the Notice of Restr |
|
| May 31, 2024 |
Inogen, Inc. Conflict Minerals Report as required by Items 1.01 of this Form SD. Exhibit 1.01 Inogen, Inc. Conflict Minerals Report For The Reporting Period from January 1, 2023 to December 31, 2023 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Inogen’s objectives for its conflict minerals polic |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 001-36309 33-0989359 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 859 Ward Drive, Goleta, CA 93111 (Address of principal executive offices) (Zip Code) M |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 15, 2024 |
Separation Agreement and Release by and between the Company and Stanislav Glezer, dated May 10, 2024 Exhibit 10.1 SEVERANCE AGREEMENT AND RELEASE This Severance Agreement and Release (“Agreement”) is made by and between Stanislav Glezer (“Employee”) and Inogen, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee signed an At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement with the C |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, I |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 7, 2024 |
Inogen Announces First Quarter 2024 Financial Results Exhibit 99.1 Inogen Announces First Quarter 2024 Financial Results GOLETA, Calif., – May 07, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024. “We are pleased to be off to a solid start at Inogen in 2024. Looking forward, we remain focused |
|
| April 23, 2024 |
INGN / Inogen, Inc. / Divisadero Street Capital Management, LP Passive Investment SC 13G 1 d1103687613-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Inogen, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45780L104 (CUSIP Number) April 17, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) Defin |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 1, 2024 |
Form of Michael Bourque Inducement Award Restricted Stock Unit Agreement - Performance-Based Exhibit 99.2 INOGEN, INC. INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT (PERFORMANCE-BASED) The award (“Award”) provided pursuant to this Restricted Stock Unit Agreement (Performance-Based) (this “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”) and Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A. Unless otherw |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inogen, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Common Stock, par value $0.0 |
|
| March 1, 2024 |
Employment Contract by and between the Company and Grégoire Ramade, dated October 5, 2023 Exhibit 10.44 INDEFINITE-TERM EMPLOYMENT CONTRACT CONTRAT DE TRAVAIL A DUREE INDETERMINEE Between: Entre : PHYSIO-ASSIST, a simplified joint-stock company under French law, with its registered office located at 31 Résidence Parc Club Du Golf, 13100 Aix-en-Provence, France, registered at the Trade Register of Aix-en-Provence under the number 753 793 827. PHYSIO-ASSIST, une société par actions simpl |
|
| March 1, 2024 |
Exhibit 97.1 INOGEN, INC. CLAWBACK POLICY This Inogen, Inc. Clawback Policy (this “Policy”) was approved effective as of October 2, 2023 (the “Effective Date”) by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Inogen, Inc. (the “Company”). This Policy is adopted pursuant to and intended to comply with Rule 5608 (Recovery of Erroneously Awarded Compensation) |
|
| March 1, 2024 |
Exhibit 10.45 ADDENDUM No. 1 TO THE EMPLOYMENT CONTRACT AVENANT N°1 AU CONTRAT DE TRAVAIL Between: Entre : PHYSIO-ASSIST, a simplified joint-stock company under French law, with its registered office located at 31 Résidence Parc Club Du Golf, 13100 Aix-en-Provence, France, registered at the Trade Register of Aix-en-Provence under the number 753 793 827. PHYSIO-ASSIST, une société par actions simpl |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on March 1, 2024 As filed with the Securities and Exchange Commission on March 1, 2024 Registration Statement No. |
|
| March 1, 2024 |
Form of Michael Bourque Inducement Award Restricted Stock Unit Agreement - Time-Based Exhibit 99.1 INOGEN, INC. INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT (TIME-BASED) The award (“Award”) provided pursuant to this Restricted Stock Unit Agreement (Time-Based) (this “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”) and Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A. Unless otherwise defined he |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inogen, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Common Stock, par value $0.0 |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on March 1, 2024 As filed with the Securities and Exchange Commission on March 1, 2024 Registration Statement No. |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name |
|
| February 27, 2024 |
Exhibit 99.1 Inogen Announces Fourth Quarter and Full-Year 2023 Financial Results Fourth quarter 2023 revenue of $75.9 million; full-year 2023 revenue of $315.7 million Goleta, CA – February 27, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the f |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2024 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2024 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 14, 2024 |
INGN / Inogen, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 13)* Inogen, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 45780L104 (CUSIP Number) Eddie C. Brown Brown Capital Managem |
|
| February 14, 2024 |
INGN / Inogen, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Inogen, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45780L104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 13, 2024 |
INGN / Inogen, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01189-inogeninc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Inogen Inc Title of Class of Securities: Common Stock CUSIP Number: 45780L104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| January 24, 2024 |
Exhibit 10.1 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this “Agreement”) is made and effective as of March 4, 2024 (the “Effective Date”), by and between Inogen, Inc., a Delaware corporation (the “Company”), and Michael Joseph Bourque (the “Executive”). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Execut |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 24, 2024 |
Inogen Names Michael Bourque As New Chief Financial Officer Exhibit 99.1 Inogen Names Michael Bourque As New Chief Financial Officer Goleta, CA – January 24, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Michael Bourque as Chief Financial Officer, effective March 4, 2024. Mr. Bourque has served as Treasurer and Chief Financial Off |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 02, 2024 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 27, 2023 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Nabil Shabshab (“Employee”) and Inogen, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed at-will by the Company; WHEREAS, Employee signed an Employment and Severance Agreement with |
|
| November 13, 2023 |
Exhibit 10.1 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this “Agreement”) is made and effective as of November 10, 2023 (the “Effective Date”), by and between Inogen, Inc., a Delaware corporation (the “Company”), and Kevin Smith (the “Executive”). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Executive’s e |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 13, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Growth and Organizational Transformation GOLETA, Calif., November 13, 2023 – Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respirato |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGE |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 7, 2023 |
Inogen Announces Third Quarter 2023 Financial Results Exhibit 99.1 Inogen Announces Third Quarter 2023 Financial Results GOLETA, Calif., November 07, 2023 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights • Reported total revenue of $84.0 milli |
|
| September 18, 2023 |
Exhibit 99.1 Inogen Completes Acquisition of Physio-Assist Acquisition Expands Inogen’s Global Respiratory Care Presence by Addressing the Sizeable, Growing and Underserved Airway Clearance Market Opportunity GOLETA, Calif., September 18, 2023 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 01, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 7, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE INOGEN ANNOUNCES CFO TRANSITION PLAN – Names Mike Sergesketter as Interim Chief Financial Officer– –Reaffirms 2023 Financial Guidance– Goleta, CA – September 7, 2023 – Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mike Sergesketter as Interim C |
|
| September 7, 2023 |
Offer Letter by and between Inogen, Inc. and Michael K. Sergesketter, dated September 6, 2023. Exhibit 10.1 September 6, 2023 Michael K. Sergesketter 9501 S 720 W Holland, IN 47541 VIA E-MAIL to [email protected] Dear Michael, Inogen, Inc. (the "Company" or "lnogen") is pleased to make the following offer of employment to you for the position of interim Executive Vice President, Chief Financial Officer, reporting to the Company's President and Chief Executive Officer ("CEO"). You will render |
|
| August 11, 2023 |
Severance Agreement and Release between the Company and George Parr, dated July 31, 2023. Exhibit 10.1 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between George Parr (“Employee”) and Inogen, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”) as of July 31, 2023 ("Effective Date”). WHEREAS, Employee signed an At-Will Employment, Confidential Information, Invention Assignment, |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ®® UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, |
|
| August 8, 2023 |
DocuSign Envelope ID: 0FF373E1-3F98-4EB7-A6C9-B5DAC2B8E8B9 Exhibit 10.5 STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET 1. Basic Provisions ("Basic Provisions"). 1.1 Parties. This Lease ("Lease"), dated for reference purposes only July 27, 2023, is made by and between Townsgate Business Park 2, LLC, a Delaware limited liability company and Majestic Luna 2, LLC, a Delaware limited liability |
|
| August 7, 2023 |
Inogen Announces Second Quarter 2023 Financial Results Exhibit 99.1 Inogen Announces Second Quarter 2023 Financial Results GOLETA, Calif., August 07, 2023 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 and Recent Business Highlights All comparisons are to the prior year period |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 24, 2023 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated July 14, 2023 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| July 24, 2023 |
INGN / Inogen Inc / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Inogen, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45780L104 (CUSIP Number) July 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 18, 2023 |
Exhibit 10.1 ASSIGNMENT AND ASSUMPTION OF LEASE AGREEMENT This ASSIGNMENT AND ASSUMPTION OF LEASE AGREEMENT (“Agreement”) is made and entered into as of July 13, 2023, by and between INOGEN, INC., a Delaware corporation (“Assignor”), and SONOS, INC., a Delaware corporation (“Assignee”), with reference to the facts set forth in the Recitals below. RECITALS A. RAF PACIFICA GROUP – REAL ESTATE FUND I |
|
| July 13, 2023 |
Exhibit 2.1 10 JULY 2023 Between Mr. Adrien MITHALAL Mr. Jean-Sébastien LANTZ Mrs. Anne REISER CAAP CREATION SOCIETE DE CAPITAL RISQUE PROVENCALE ET CORSE REGION SUD INVESTISSEMENT Mérieux Participations 2 Relyens Innovation Santé the holders of Exercisable Securities listed in Schedule A As the Sellers And Inogen, Inc. As the Purchaser In the presence of Physio-Assist As the Company SHARE PURCHAS |
|
| July 13, 2023 |
Exhibit 99.1 Inogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-Assist Acquisition Enables Evolution to a Global Respiratory Care Company by Adding a Sizable, Growing and Underserved Airway Clearance Market Opportunity Inogen Provides Preliminary, Unaudited Second Quarter Financial Update Inogen to Announce Second Quarter Financial Results on August 7, 2023 GOLETA, Calif., |
|
| July 13, 2023 |
Terms and Conditions of Convertible Bonds Issued by Physio-Assist dated July 10, 2023 Exhibit 10.1 TERMS AND CONDITIONS OF CONVERTIBLE BONDS ISSUED BY PHYSIO-ASSIST This document sets forth the terms and conditions (the “Terms and Conditions”) of the bonds convertible into B Preferred Shares (the “Convertible Bonds”), issued by PHYSIO-ASSIST, a French société par actions simplifiée having its registered office located at 31 Parc du Golf – CS 90519, 13593 Aix-en-Provence, registered |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 10, 2023 |
INGN / Inogen Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Inogen Inc. Title of Class of Securities: Common Stock CUSIP Number: 45780L104 Date of Event Which Requires Filing of this Statement: June 30, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1( |
|
| June 7, 2023 |
As filed with the Securities and Exchange Commission on June 6, 2023 As filed with the Securities and Exchange Commission on June 6, 2023 Registration Statement No. |
|
| June 7, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inogen, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per sh |
|
| June 6, 2023 |
Exhibit 10.1 INOGEN, INC. 2023 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options, Nonstat |
|
| June 6, 2023 |
Form of Stock Option Agreement under the 2023 Equity Incentive Plan Exhibit 10.2 INOGEN, INC. 2023 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Inogen, Inc. 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Agreement (the “Agreement”), including the Notice of Stock Option Grant (the “Notice of Grant”) and Terms and Conditions of Stock Option Grant, attached her |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 6, 2023 |
Form of Restricted Stock Unit Agreement (Time-Based) under the 2023 Equity Incentive Plan Exhibit 10.3 INOGEN, INC. 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (TIME-BASED) Unless otherwise defined herein, the terms defined in the Inogen, Inc. 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (Time-Based) (this “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the “Notice of Gra |
|
| June 6, 2023 |
Form of Restricted Stock Unit Agreement (Performance-Based) under the 2023 Equity Incentive Plan Exhibit 10.4 INOGEN, INC. 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (PERFORMANCE-BASED) Unless otherwise defined herein, the terms defined in the Inogen, Inc. 2023 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (Performance-Based) (this “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the |
|
| May 30, 2023 |
Inogen, Inc. Conflict Minerals Report as required by Items 1.01 of this Form SD. Exhibit 1.01 Inogen, Inc. Conflict Minerals Report For The Reporting Period from January 1, 2022 to December 31, 2022 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Inogen’s objectives for its conflict minerals polic |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 001-36309 33-0989359 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 301 Coromar Drive, Goleta, CA 93117 (Address of principal executive offices) (Zip Code |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, I |
|
| May 5, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Inogen, Inc.* Name of Subsidiary Jurisdiction of Incorporation or Organization Inogen Europe B.V. Netherlands * Inclusion on the list above is not an admission that any of the above entities, individually or in the aggregate, constitutes a significant subsidiary within the meaning of Rule 1-02(w) of Regulation S-X and Item 601(b)(21)(ii) of Regulation S-K. |
|
| May 4, 2023 |
Exhibit 99.1 Inogen Announces First Quarter 2023 Financial Results Total Revenue of $72.2 Million In Line with Company Expectations Rental Revenue Year-over-Year Growth of 25% GOLETA, Calif., May 04, 2023 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) Defin |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 22, 2023 |
Exhibit 99.1 Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda GOLETA, Calif., March 22, 2023 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of Directors, effective April 1, 2023. The company |
|
| February 24, 2023 |
As filed with the Securities and Exchange Commission on February 24, 2023 S-8 1 ingn-2023-02-24-s-8.htm S-8 As filed with the Securities and Exchange Commission on February 24, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Inogen, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0989359 (State or other jurisdiction of inc |
|
| February 24, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inogen, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per sh |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 23, 2023 |
Exhibit 99.1 Inogen Announces Fourth Quarter and Full Year 2022 Financial Results Fourth Quarter Year-over-Year Revenue Growth of 15.3% Full Year 2022 Year-over-Year Revenue Growth of 5.4% GOLETA, Calif., February 23, 2023 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the f |
|
| February 14, 2023 |
INGN / Inogen Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0081791-1sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 12)* Inogen, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 45780L104 (CUSIP Number) Edd |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 06, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 10, 2023 |
Transition Agreement and Release between the Company and Bart Sanford, dated February 6, 2023. Exhibit 10.1 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Bart Sanford (“Employee”) and Inogen, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee has been employed at-will by the Company pursuant to the terms and conditions of initial offer letter and agreements |
|
| February 9, 2023 |
INGN / Inogen Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Inogen Inc. Title of Class of Securities: Common Stock CUSIP Number: 45780L104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| January 10, 2023 |
Exhibit 99.1 Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations Inogen to Present at J.P. Morgan Healthcare Conference This Week Inogen to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 GOLETA, Calif., January 10, 2023 - Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory produc |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 22, 2022 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGE |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 2, 2022 |
Exhibit 99.1 Inogen Announces Third Quarter 2022 Financial Results Double Digit Year-over-Year Revenue Growth of 13.2% Constant Currency Year-over-Year Revenue Growth of 14.5% GOLETA, Calif., November 02, 2022 ? Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended |
|
| November 2, 2022 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF INOGEN, INC. (as amended and restated on October 27, 2022) TABLE OF CONTENTS Page ARTICLE I ? CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II ? MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS? MEETINGS 9 2.6 QUORUM 9 2.7 ADJO |
|
| October 11, 2022 |
INGN / Inogen Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 11)* Inogen, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 45780L104 (CUSIP Number) Eddie C. Brown Brown Capital Managem |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, IN |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 4, 2022 |
Exhibit 99.1 Inogen Announces Second Quarter 2022 Financial Results Robust Sequential Revenue Growth Driven by Fulfilled Demand GOLETA, Calif., August 04, 2022 ? Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2022 and provided a business update. Seco |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 001-36309 33-0989359 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 301 Coromar Drive, Goleta, CA 93117 (Address of principal executive offices) (Zip Code |
|
| May 31, 2022 |
Inogen, Inc. Conflict Minerals Report as required by Items 1.01 of this Form SD Exhibit 1.01 Inogen, Inc. Conflict Minerals Report For The Reporting Period from January 1, 2021 to December 31, 2021 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Inogen’s objectives for its conflict minerals polic |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, I |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 5, 2022 |
Inogen Announces First Quarter 2022 Financial Results – Q1 2022 Total Revenue of $80.4 million – Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces First Quarter 2022 Financial Results – Q1 2022 Total Revenue of $80.4 million – Goleta, California, May 5, 2022 — Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three months ended March 31, 2022. First Quarter 2022 Highlig |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 23, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Board of Director Changes Glenn Boehnlein, Kevin King and Mary Kay Ladone Appointed as Independent Directors Goleta, California, March 23, 2022 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Glenn Boehnlein, Kevin King, and Ma |
|
| March 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 4, 2022 |
Exhibit 10.1 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this ?Agreement?), is made and effective as of March 21, 2022 (the ?Effective Date?), by and between Inogen, Inc., a Delaware corporation (the ?Company?), and Kristin A. Caltrider (the ?Executive?). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Execut |
|
| March 4, 2022 |
Inogen Names Kristin Caltrider as Chief Financial Officer Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Names Kristin Caltrider as Chief Financial Officer Goleta, California, March 4, 2022 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Kristin Caltrider as EVP & Chief Financial Officer, effective March 21, 2022. Ms. Caltrider succeeds Mik |
|
| March 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 24, 2022 |
s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact nam |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 24, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Fourth Quarter and Full Year 2021 Financial Results ? Q4 2021 Total Revenue increased 3.3% year-over-year to $76.4 million ? Goleta, California, February 24, 2022 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three- and |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2022 |
INGN / Inogen Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 10)* Inogen, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 45780L104 (CUSIP Number) Eddie C. Brown Brown Capital Managem |
|
| February 10, 2022 |
INGN / Inogen Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Inogen Inc. Title of Class of Securities: Common Stock CUSIP Number: 45780L104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13 |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 10, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Preliminary, Unaudited Full Year and Fourth Quarter 2021 Revenue Results ? Q4 2021 Total Preliminary Revenue of $75.9 to $76.9 million ? ? Provides Supply Chain and EU Operations Update ? Goleta, California, January 10, 2022 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecar |
|
| January 10, 2022 |
Inogen, Inc. Overview 40th Annual J.P. Morgan HealthCare Conference January 12, 2022 Exhibit 99.2 Notice Regarding Forward-Looking Statements These slides and the accompanying oral presentation (the ?Presentation?) include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based o |
|
| December 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 30, 2021 |
Exhibit 10.1 INOGEN, INC. CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is made and entered into as of December 29, 2021 (the ?Effective Date?) by and between Inogen, Inc. (the ?Company?), and Raymond Huggenberger (?Consultant?) (each herein referred to individually as a ?Party,? or collectively as the ?Parties?). Consultant has voluntarily resigned from the Company?s board of |
|
| December 30, 2021 |
INOGEN APPOINTS ELIZABETH MORA AS BOARD CHAIRPERSON - Ray Huggenberger Retires from Board - Exhibit 99.1 FOR IMMEDIATE RELEASE INOGEN APPOINTS ELIZABETH MORA AS BOARD CHAIRPERSON - Ray Huggenberger Retires from Board - Goleta, CA ? December 30, 2021 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Elizabeth (Beth) Mora was elected as Board Chairperson. Ms. Mora has served as a member |
|
| December 13, 2021 |
Transition Agreement and Release between the Company and Alison Bauerlein, dated December 10, 2021. Exhibit 10.2 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (?Agreement?) is made by and between Alison Bauerlein (?Employee?) and Inogen, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). WHEREAS, Employee has been employed at-will by the Company pursuant to that certain Amended and Restated Employment Agreement date |
|
| December 13, 2021 |
INOGEN ANNOUNCES CFO TRANSITION PLAN – Names Mike Sergesketter as Interim Chief Financial Officer– Exhibit 99.1 FOR IMMEDIATE RELEASE INOGEN ANNOUNCES CFO TRANSITION PLAN ? Names Mike Sergesketter as Interim Chief Financial Officer? Goleta, CA ? December 13, 2021 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mike Sergesketter as Interim Chief Financial Officer, effective im |
|
| December 13, 2021 |
Offer Letter by and between the Company and Michael K. Sergesketter, dated December 10, 2021. Exhibit 10.1 December 10, 2021 Michael K. Sergesketter VIA E-MAIL Dear Michael, Inogen, Inc. (the ?Company? or ?Inogen?) is pleased to make the following offer of employment to you for the position of interim Executive Vice President, Chief Financial Officer, reporting to the Company?s President and Chief Executive Officer (?CEO?). You will render such business and professional services in the per |
|
| December 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGE |
|
| November 4, 2021 |
Transition Agreement and Release, dated September 30, 2021, between the Company and Brenton Taylor. Exhibit 10.3 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (?Agreement?) is made by and between Brenton Taylor (?Employee?) and Inogen, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). WHEREAS, Employee has been employed at-will by the Company pursuant to that certain Amended and Restated Employment Agreement dated |
|
| November 4, 2021 |
Exhibit 10.4 INOGEN, INC. AMENDED AND RESTATED EMPLOYMENT AND SEVERANCE AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AND SEVERANCE AGREEMENT (this ?Agreement?), is made and effective as of October 11, 2021 (the ?Effective Date?), by and between Inogen, Inc., a Delaware corporation (the ?Company?), and Stanislav Glezer (the ?Executive?). This Agreement amends and restates the Employment and Sever |
|
| November 4, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE This First Amendment to Lease (?Amendment?) is entered into, and dated for reference purposes, as of June 17, 2021 (the ?Execution Date?) by and between RAF PACIFICA GROUP ? REAL ESTATE FUND IV, LLC, a California limited liability company; APG HOLLYWOOD CENTER, LLC, a California limited liability company; and APG AIRPORT FREEWAY CENTER, LLC, a California limit |
|
| November 4, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Third Quarter 2021 Financial Results ? Q3 2021 Total Revenue increased 25.3% from the same period in 2020 to $93.1 million ? Goleta, California, November 4, 2021 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three month |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 4, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| September 20, 2021 |
INGN / Inogen Inc / Novo Holdings A/S - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Inogen, Inc. (Name of Issuer) Common Stock (Title of class of securities) 45780L104 (CUSIP number) September 9, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 5, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Second Quarter 2021 Financial Results ? Q2 2021 Record Total Revenue of $101.6 million, up 41.7% from the same period in 2020 ? Goleta, California, August 4, 2021 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three mont |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 4, 2021 |
Employment and Severance Agreement, between the Company and Jason M. Somer, dated July 12, 2021. Exhibit 10.2 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this ?Agreement?), is made and effective as of July 12, 2021 (the ?Effective Date?), by and between Inogen, Inc., a Delaware corporation (the ?Company?), and Jason M. Somer (the ?Executive?). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Executive?s e |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, IN |
|
| August 4, 2021 |
Employment and Severance Agreement, between the Company and Stanislav Glezer, dated June 21, 2021. Exhibit 10.1 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this ?Agreement?), is made and effective as of June 21, 2021 (the ?Effective Date?), by and between Inogen, Inc., a Delaware corporation (the ?Company?), and Stanislav Glezer (the ?Executive?). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Executive?s |
|
| August 4, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Second Quarter 2021 Financial Results ? Q2 2021 Record Total Revenue of $101.6 million, up 41.7% from the same period in 2020 ? Goleta, California, August 4, 2021 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three mont |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 27, 2021 |
Inogen, Inc. Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. EX-1.01 2 ingn-ex1016.htm EX-1.01 Exhibit 1.01 Inogen, Inc. Conflict Minerals Report For The Reporting Period from January 1, 2020 to December 31, 2020 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Inogen’s objectiv |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 001-36309 33-0989359 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 301 Coromar Drive, Goleta, CA 93117 (Address of principal executive offices) (Zip Code |
|
| May 24, 2021 |
Inogen Strengthens Board of Directors with Addition of Elizabeth Mora Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Strengthens Board of Directors with Addition of Elizabeth Mora Goleta, California, May 24, 2021 ?Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Elizabeth (Beth) Mora has been appointed to its Board of Directors, effective May 24, 2021. In addition, Ms. |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, I |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 4, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces First Quarter 2021 Financial Results ? Q1 2021 Total Revenue of $86.9 million ? ? Q1 2021 Rental Revenue of $9.9 million, up 84.2% from the same period in 2020 ? Goleta, California, May 4, 2021 ? Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported finan |
|
| May 4, 2021 |
Employment and Severance Agreement between the Company and George Parr, dated April 12, 2021. Exhibit 10.6 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this ?Agreement?), is made and effective as of April 12, 2021 (the ?Effective Date?), by and between Inogen, Inc., a Delaware corporation (the ?Company?), and George Parr (the ?Executive?). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Executive?s emp |
|
| April 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Inogen Inc. Title of Class of Securities: Common Stock CUSIP Number: 45780L104 Date of Event Which Requires Filing of this Statement: March 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1 |
|
| April 7, 2021 |
EX-99.1 4 ingn-ex99121.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Appointment of Chief Commercial Officer, Transition of Certain Officers, and Preliminary, Unaudited First Quarter 2021 Revenue Range - George Parr to join as Executive Vice President and Chief Commercial Officer Effective April 12, 2021 - Goleta, California, April 7, 2021 —Inogen, Inc. (NASDAQ: INGN), a medical |
|
| April 7, 2021 |
Transition Agreement and Release between the Company and Byron Myers, dated April 5, 2021. EX-10.2 3 ingn-ex10222.htm EX-10.2 Exhibit 10.2 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Byron Myers (“Employee”) and Inogen, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee has been employed at-will by the Company pursuant to that certain Amended and Rest |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 7, 2021 |
Transition Agreement and Release between the Company and Arron Retterer, dated April 5, 2021. Exhibit 10.1 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (?Agreement?) is made by and between Arron Retterer (?Employee?) and Inogen, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). WHEREAS, Employee has been employed at-will by the Company pursuant to that certain Employment and Severance Agreement dated August |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State |
|
| March 23, 2021 |
DEFA14A 1 ingn-defa14a20210510.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| February 24, 2021 |
EX-99.1 2 ingn-ex9916.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Fourth Quarter 2020 Financial Results – Q4 2020 Total Revenue of $74.0 million – – Q4 2020 Rental Revenue of $9.4 million, up 71.7% from the same period in 2019 – Goleta, California, February 24, 2021 — Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in t |
|
| February 24, 2021 |
Exhibit 10.39 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Scott Wilkinson (“Employee”) and Inogen, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee has been employed at-will by the Company pursuant to that certain Amended and Restated Employment and Severance |
|
| February 24, 2021 |
EX-10.40 3 ingn-ex1040167.htm EX-10.40 Exhibit 10.40 FIRST AMENDMENT TO MERGER AGREEMENT This Amendment, dated January 18, 2021, is made to the August 6, 2019 Agreement And Plan Of Merger (the “Merger Agreement”) by and among Inogen, Inc., a Delaware corporation (“Buyer”), and Gregory J. Kapust (“Mr. Kapust”) as the representative of the Entitled Holders (the “Entitled Holders’ Agent”) and as shar |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 17, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Inogen, Inc. (Name of Issuer) Common Stock (Title of class of securities) 45780L104 (CUSIP number) February 12, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 16, 2021 |
Inogen Strengthens Board of Directors with Addition of Kristen Miranda EX-99.1 2 ingn-ex9916.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Strengthens Board of Directors with Addition of Kristen Miranda Goleta, California, February 16, 2021 —Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Kristen Miranda has been appointed to its Board of Directors, effect |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 9)* Inogen, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 45780L104 (CUSIP Number) Eddie C. Brown Brown Capital Manageme |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Inogen Inc. Title of Class of Securities: Common Stock CUSIP Number: 45780L104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| January 25, 2021 |
Transition Agreement and Release between the Company and Scott Wilkinson, dated January 22, 2021. EX-10.2 3 ingn-ex10258.htm EX-10.2 Exhibit 10.2 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Scott Wilkinson (“Employee”) and Inogen, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee has been employed at-will by the Company pursuant to that certain Amended and |
|
| January 25, 2021 |
Employment and Severance Agreement between the Company and Nabil Shabshab, dated January 22, 2021. Exhibit 10.1 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this “Agreement”) is made and effective as of February 8, 2021 (the “Effective Date”), by and between Inogen, Inc., a Delaware corporation (the “Company”), and Nabil Shabshab (the “Executive”). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Executive’s |
|
| January 25, 2021 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 11, 2021 |
Company Overview January 2021 Exhibit 99.1 Notice Regarding Forward-Looking Statements These slides and the accompanying oral presentation (the “Presentation”) include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently available to management. These |
|
| January 11, 2021 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 4, 2020 |
Employment and Severance Agreement, dated August 17, 2020, between the Company and Arron Retterer Exhibit 10.1 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This EMPLOYMENT AND SEVERANCE AGREEMENT (this “Agreement”), is made and effective as of August 17, 2020 (the “Effective Date”), by and between Inogen, Inc., a Delaware corporation (the “Company”), and Arron Retterer (the “Executive”). WITNESSETH: WHEREAS, the Company desires to enter into this Agreement embodying the terms of Executive’s |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGE |
|
| November 4, 2020 |
Inogen Announces Third Quarter 2020 Financial Results – Q3 2020 Total Revenue of $74.3 million – Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Third Quarter 2020 Financial Results – Q3 2020 Total Revenue of $74.3 million – Goleta, California, November 4, 2020 — Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended September 30, 2020. Third Quart |
|
| August 5, 2020 |
Third Amendment to lease, dated July 14, 2020, between Registrant and Rockbridge Investments, L.P. Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”), dated July 14, 2020, for reference purposes only, is made and entered into by and between ROCKBRIDGE INVESTMENTS, L.P., a California limited partnership ("Landlord"), and INOGEN, INC., a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant entered into that certain Multi-Purpose Commercial Building L |
|
| August 5, 2020 |
Inogen Announces Second Quarter 2020 Financial Results – Q2 2020 Total Revenue of $71.7 million – Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen Announces Second Quarter 2020 Financial Results – Q2 2020 Total Revenue of $71.7 million – Goleta, California, August 4, 2020 — Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended June 30, 2020. Second Quarter 20 |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, IN |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 9, 2020 |
Inogen CEO Announces Intent to Retire Before End of 2021; Inogen Commences Search for Successor Exhibit 99.1 FOR IMMEDIATE RELEASE Inogen CEO Announces Intent to Retire Before End of 2021; Inogen Commences Search for Successor Goleta, California, June 9, 2020 — Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that in connection with Inogen’s succession planning activities, Scott Wilkinson, the |
|
| June 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 INOGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36309 33-0989359 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 001-36309 33-0989359 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 326 Bollay Drive, Goleta, CA 93117 (Address of principal executive offices) (Zip Code) |
|
| May 28, 2020 |
Inogen, Inc. Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Inogen, Inc. Conflict Minerals Report For The Reporting Period from January 1, 2019 to December 31, 2019 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Inogen’s objectives for its conflict minerals polic |
